Transforming Point-of-Care Testing

Company History

Prominex was founded in 2018 by individuals passionate about transforming molecular point-of-care testing. Together, we are focused on developing near-patient testing with rapid, central lab accuracy for clinically actionable results and cost-effective testing kits for broad accessibility. Our Prominex System is a transformative molecular diagnostic testing solution for near patient care settings designed to deliver results in 5 minutes. The novel molecular amplification and detection technologies enables the development of fast, accurate, easy-to-use, multiplexed, and low-cost molecular diagnostic assays providing unprecedented value to practitioners.

Initial assay development focus is on SARS-CoV-2, Sexually Transmitted Infections and other Respiratory Tract Infections. Broad IP portfolio protects our novel enzyme, molecular chemistry and detection technologies. The leadership team has proven experience developing best-in-class molecular diagnostic assays and medical devices. Seed capital financing provided by Casdin Capital LLC and the founding CEO.

Prominex Lab
Doctor by bedside


Improve global access to rapid, accurate and affordable infectious disease molecular diagnostics.  


Prominex is committed to developing innovative, high quality, rapid point of care molecular assays for use in diagnosing infectious diseases. Our commitment is guided by our focus on and understanding of patient and user needs. Our systems and processes enable Prominex to meet applicable local, state, federal and international requirements as well as work with partners to manufacture products that meet the needs of our customers.

Prominex Technology


Our leadership team is comprised of industry experts in molecular diagnostics product development.

Board of Directors


Casdin Capital